10-Q: Revelation Biosciences Reports Q2 2024 Results, Faces Going Concern Uncertainty Amidst Legal Setback

Sentiment:

Quarterly Report 9 August 2024 4:01 PM

📋All filings for Revelation Biosciences, INC

Revelation Biosciences reported a net loss of $11.1 million for the first half of 2024 and faces substantial doubt about its ability to continue as a going concern due to recurring losses and the need for additional capital.

Capital raiseThe company plans to seek additional funding through public or private equity or debt financings.The company may not be able to obtain financing on acceptable terms, or at all.The terms of any financing may adversely affect the holdings or the rights of the company's stockholders.

Worse than expectedThe company's net loss of $11.1 million for the first half of 2024 is significantly worse than the net income of $4.7 million for the same period in 2023.The company's accumulated deficit has increased to $36.5 million, indicating a worsening financial position.The company's management has expressed substantial doubt about its ability to continue as a going concern, which is a negative outlook.

Summary

Revelation Biosciences, a clinical-stage biopharmaceutical company, reported a net loss of $11.1 million for the six months ended June 30, 2024, compared to a net income of $4.7 million for the same period in 2023.
The company's accumulated deficit has reached $36.5 million as of June 30, 2024.
Operating expenses totaled $4.4 million for the first half of 2024, with research and development expenses at $2.1 million and general and administrative expenses at $2.3 million.
The company's cash and cash equivalents stood at $12.1 million as of June 30, 2024.
Revelation Biosciences has never generated revenue and does not expect to do so until it successfully completes development and obtains regulatory approval for its product candidates, which is not expected for several years.
The company has raised $49.3 million through the issuance and sale of capital stock since its inception.
A recent legal judgment against the company for $7.3 million, plus $0.2 million in costs, has significantly impacted its financial results.
The company's management has expressed substantial doubt about its ability to continue as a going concern due to its recurring losses and the need for additional capital.

Sentiment

Score: 2

Explanation: The document indicates significant financial challenges, including substantial losses, a large accumulated deficit, and a going concern warning. The legal judgment and the need for additional capital further contribute to a negative outlook.

Positives

The company has $12.1 million in cash and cash equivalents.
The company has raised $49.3 million through the issuance and sale of capital stock since its inception.

Negatives

The company reported a net loss of $11.1 million for the first half of 2024.
The company has an accumulated deficit of $36.5 million.
The company has never generated revenue and does not expect to do so for several years.
The company faces a legal judgment of $7.3 million plus $0.2 million in costs.
Management has expressed substantial doubt about the company's ability to continue as a going concern.

Risks

The company's current cash and cash equivalents balance may not be sufficient to sustain operations within one year.
The company may not be able to obtain additional financing on acceptable terms, or at all.
Failure to obtain funding could force the company to delay, reduce, or eliminate research and development programs.
The company is subject to risks associated with clinical trials and regulatory approvals.
The company is subject to risks associated with legal proceedings.

Future Outlook

The company expects to continue to incur significant operating and net losses, as well as negative cash flows from operations, for the foreseeable future as it continues to complete all necessary product development or future commercialization efforts. The company plans to seek additional funding through public or private equity or debt financings.

Management Comments

The company's management has expressed substantial doubt about its ability to continue as a going concern.
Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives.

Industry Context

The biopharmaceutical industry is characterized by high research and development costs, long development timelines, and significant regulatory hurdles. Revelation Biosciences is facing challenges common to early-stage companies in this sector, including the need for substantial capital to fund operations and the uncertainty of clinical trial outcomes.

Comparison to Industry Standards

Many early-stage biopharmaceutical companies experience significant losses and negative cash flows as they invest heavily in research and development.
The need for additional capital is a common challenge for companies in this sector, and Revelation's plan to seek additional funding is consistent with industry practices.
The legal judgment against the company is an unusual event that has significantly impacted its financial results, and is not typical of the industry.
The company's cash position of $12.1 million is relatively low for a company with ongoing clinical programs, and the company will need to raise additional capital to continue operations.
Comparable companies in the clinical-stage biopharmaceutical space include companies such as Athersys, Inc. and Ocugen, Inc., which also face similar challenges in funding and clinical development.

Legal Proceedings

LifeSci Capital LLC filed an action against the company seeking damages for unpaid banking and advisory fees, resulting in a judgment against the company for $7.3 million plus $0.2 million in costs.
A-IR Clinical Research Ltd. filed a claim against the company for unpaid invoices, which was settled on April 26, 2024.

Stakeholder Impact

Shareholders face the risk of dilution from potential capital raises and the possibility of the company not continuing as a going concern.
Employees may be impacted by potential delays or reductions in research and development programs.
Customers and suppliers may be impacted by the company's financial instability.

Next Steps

The company plans to seek additional funding through public or private equity or debt financings.
The company will continue the research and development of its product candidates.
The company will continue to monitor the legal proceedings and their impact on the company.

Key Dates

Date	Description
2019-11-20	The company was incorporated in the state of Delaware.
2022-01-25	The company issued warrants to an institutional investor to purchase up to 2,464 shares of common stock at an exercise price of $3,454.50 per share.
2022-02-02	The company received a notice of cash exercise for the company's Rollover Warrants for 2 shares of common stock at a purchase price of $5,073.
2022-02-18	LifeSci Capital LLC filed an action against the company seeking damages for unpaid banking and advisory fees.
2022-07-28	The company closed a public offering and issued warrants to purchase an aggregate of 7,937 shares of common stock at an exercise price of $630.00 per share.
2022-12-19	The company closed the sale of one share of the company's Series A Preferred Stock to its Chief Executive Officer for $5,000.00.
2023-01-25	The company effected a 1-for-30 reverse stock split of its shares of common stock.
2023-01-30	The outstanding share of Series A Preferred Stock was automatically redeemed for $5,000.00.
2023-02-09	The SEC declared the company's Form S-1 effective.
2023-02-13	The company closed a public offering of common stock, pre-funded warrants, and common stock warrants.
2023-02-14	The Class C Common Stock Warrants expire on this date in 2028.
2023-04-06	The company received notices of cash exercise for the Class C Pre-Funded Warrants.
2023-04-18	The company issued 140 shares of common stock in connection with vested Rollover RSU awards.
2023-07-14	An amendment to the 2021 Equity Incentive Plan was approved at the company's 2023 Annual Meeting of Stockholders.
2023-12-01	A Magistrate Judge issued a report recommending summary judgment in favor of LifeSci.
2023-12-15	The company filed objections to the Magistrate's report.
2024-01-25	The company effected a 1-for-30 reverse stock split of its outstanding shares of common stock.
2024-01-29	The company issued 3,398 shares of common stock in connection with notices of alternative cashless exercise for the Class C Common Stock Warrants.
2024-01-31	The SEC declared the company's Form S-1 effective.
2024-02-05	The company closed a public offering of common stock, pre-funded warrants, and common stock warrants.
2024-02-13	The company received notices of cash exercise for the Class D Pre-Funded Warrants.
2024-02-14	The Class C Common Stock Warrants expire on this date in 2028.
2024-04-26	The company settled a claim with A-IR Clinical Research Ltd.
2024-05-15	An amendment to the 2021 Equity Incentive Plan was approved at the company's 2024 Annual Meeting of Stockholders.
2024-06-11	The company issued 10,460 shares of its common stock to a third party consultant for services provided.
2024-06-30	The end of the reporting period for the quarterly report.
2024-08-01	The District Court judge entered an order adopting the Magistrate Judge's report and granted the summary judgment.
2024-08-05	The date as of which the registrant had 1,643,395 shares of common stock outstanding.
2024-08-09	The date of the report.
2024-11-30	The company's lease is extended until this date.

Keywords

biopharmaceutical, clinical-stage, trained immunity, GEM-AKI, GEM-CKD, GEM-PSI, research and development, financial results, going concern, capital raise, warrants, stock options

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.